420 with CNW — Feds Announce Standardized THC Dose Researchers Must Use

The National Institute on Drug Abuse (“NIDA”), a leading health agency of the U.S. federal government, has announced a standardized THC dosage that research teams have to use from now on when studying cannabis. The standard unit set is 5mg, and the unit strictly applies to all studies that have humans as test subjects.

The federal agency noted that the current differences in the way THC is reported by researchers made it difficult for interested parties to compare the findings of different studies on the same substance. The standard dose is designed to make it easier to compare the possible adverse or medical benefits of marijuana as established by various researchers.

However, the feds admitted that it was true that the same concentration of THC could trigger different effects based on several factors, such as how it was administered, the other compounds within the marijuana sample, and the genetic constitution of the test subjects, among other variables. NIDA nonetheless reiterated that having a standardized THC dose would help in the task of comparing different studies, something that NIDA and other federal authorities regard as a high priority.

The federal notice clarifies that researchers aren’t constrained to use only 5mg as they conduct studies. Rather, they are free to use as little or as much THC as they want, provided that they report their findings using the standard dose stipulated for all applicable studies.

The notice comes approximately a year after NIDA asked for feedback regarding a plan to set a standard unit for THC while marijuana research is conducted. The federal agency now reveals that its decision was informed by views of cannabis experts as well as the data from the responses collected from stakeholders as feedback was submitted.

The dosage guidance only applies to those scientific studies focusing on THC, and those applying to conduct such studies will be expected to determine whether and how the standard applies to their specific research. If researchers don’t want to adhere to the guidance, they are required to include a justification for such a decision while submitting their application for authorization to proceed with the study.

NIDA director Nora Volkow has previously voiced strong support for the need to come up with a standard unit for THC. Last year she commented that the complexities associated with cannabis research didn’t warrant abandoning efforts to establish a standard unit for THC. She has also openly criticized the federal scheduling of cannabis as hampering efforts to conduct research into the substance.

When future research cementing the effects of different cannabis compounds can no longer be doubted under the guise that a different dose was used to report the findings obtained, cannabis sector players that don’t make products containing THC, such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER), stand to benefit as well.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Massachusetts Firm Discovers That Tears Can Help Detect Drivers Impaired by Cannabis

Breathalyzers, blood tests and standard sobriety tests can be used by police officers to ascertain to a high degree of accuracy whether a driver has been impaired by alcohol. However, no such measures are available to law enforcement for the purpose of identifying drivers who are under the influence of marijuana. A company based in Quincy, Massachusetts, seems to have found a way to test for marijuana impairment, and the test relies on tears as samples for this test.

Impairment Measurement Marijuana and Driving (“IMMAD”) is working with the Biomedical Forensics Program of Boston University’s School of Medicine to refine how tears can be used to establish the quantity of active cannabinoids within a driver’s body as a measure of how impaired the driver may be.

The research team’s work established that a person’s tears are a good way to identify and measure which particular cannabinoids may be inactive or active. This particular sample is more specific and sensitive when compared to a person’s saliva or breath. The abstract of this research paper was discussed in April at a forensic science conference, and the paper itself will be presented later this year at a virtual conference of the Midwest Toxicology & Therapeutic Drug Monitoring Association.

Sabra B. Jones, a professor at Boston University, worked with Allen Mello, one of her graduate students, last fall and winter to document the efficacy level of relying on tears as an indicator of the magnitude of cannabinoids present in one’s body. The team relied on the understanding that since tears contain a lot more fat/lipophilic contents and since marijuana as well as its compounds are fat soluble, tears would give better test results when compared to one’s breath or saliva, which contain hardly any fats.

Recreational cannabis is legal in Massachusetts, and the research team recruited volunteers who used their own marijuana for the research. Tears and blood samples were then drawn for analysis. Mello conducted this research to fulfil the requirements of a course. The program trains people who would like to work as forensic scientists, and a chemistry/biomedical background is crucial for such forensic scientists, such as those working in crime labs. The research submitted must meet all the requirements of studies published in peer-reviewed journals, and Mello’s work met this criteria. What is left now is to develop the test further so that it can be commercialized.

Once this test method is finalized and validated by the scientific community, it could potentially play a role in the work of cannabis companies, including companies such as Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM).

NOTE TO INVESTORS: The latest news and updates relating to Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) are available in the company’s newsroom at http://cnw.fm/PACR

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Sugarmade Inc. (SGMD) Completes Lemon Glow Acquisition

Sugarmade (OTC: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, announced that it has closed on its previously announced acquisition of Lemon Glow Company Inc., including all of the company’s assets, interests, property and rights, The acquisition includes 640 acres in Lake County, California, outside of the Commercial Cannabis Cultivation Exclusion Zones; a portion of that property has already been designated for outdoor cannabis cultivation. The announcement noted that the estimated annual potential cultivation yield from the property is approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which translates to about 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total. “This step brings us closer to closing the loop on what we believe to be one of the most promising vertically integrated cannabis models in the thriving California market,” said Sugarmade CEO Jimmy Chan in the press release. “We are setting the stage to improve margins while expanding end-market access, and to grow, refine, produce, distribute, sell, and home-deliver top cannabis products in the largest and fastest growing cannabis market on the planet. This acquisition positions us to achieve that objective with a significant capacity to scale as demand for our products and services grows over time.”

To view the full press release, visit https://cnw.fm/StrLk

About Sugarmade Inc.

Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s portfolio includes CarryOutsupplies.com, SugarRush(TM), NUG Avenue and Budcars. For more information about the company, please visit www.Sugarmade.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Enters Definitive Agreement to Acquire Apothecanna, Announces AGM Voting

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness company offering premium probiotic supplements and products containing CBD, has announced plans to acquire APCNA Holdings LLC (“APCNA”). CBDHF has entered into a definitive agreement to acquire 100% of APCNA, known as Apothecanna. The company also held its annual general meeting (“AGM”) on Friday, May 14, 2021, and reported that all matters contained in the management information circulate sent to shareholders for consideration and approval were approved by the requisite majority of votes cast at the meeting. Apothecanna offers cannabis-powered body care and topical products and was the first topicals brand to operate nationally and obtain a federal trademark. The company has built a reputation for being an industry leader in the development of innovative, all-natural CBD products. The company also has a strong ecommerce focus, with an estimated 50% of revenues being generated from its online portal. The acquisition announcement noted that Apothecanna’s reported revenue of more than $4 million in 2020 doubles HempFusion’s historical revenue, and with strategic expansion already in place, the acquisition will be immediately accretive at closing. The agreement also provides HempFusion with immediate distribution to an additional 1,800 stores, including CVS. “We are incredibly excited to enter into this agreement with Apothecanna, which, on closing, will have an immediate impact on HempFusion’s revenue while significantly bolstering our distribution and ecommerce platforms,” said HempFusion co-founder and CEO Jason Mitchell, ND, in the press release. “We look forward to working to close the transaction as soon as possible.”

To view the full press releases, visit https://cnw.fm/iQ0Yu and https://cnw.fm/M97B5

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in stores or online. For more information about the company, visit www.HempFusion.com.

NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at https://cnw.fm/CBDHF

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE:7BC ) Inks White-Label Manufacturing Agreement

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness, beverage and natural products company, has signed a co-packing agreement with Riviera Beverages LLC of California. The agreement, which is the third white-label agreement BevCanna has completed, should jump start the launch of the company’s TRACE plant-based mineral and hemp-derived CBD bottled beverages in the United States and internationally. The announcement noted that BevCanna has built one of the most diverse beverage portfolios within the cannabis space. A leader in manufacturing bottled beverages in North America and abroad, Riviera has more than a decade of experience working with an array of well-known brands including Essentia, Waiakea and Aqua Hydrate. The announcement also noted that the recent additions of Raffael Kapusty and Bill Niarchos to the BevCanna team was a critical step in the company’s U.S. and international sales development. The two CPG experts will focus on scaling the points of distribution across the market and expanding BevCanna’s international CPG distribution network. “This agreement with Riviera is a significant step forward in our strategy to penetrate the U.S. and international markets with our TRACE plant-based mineral, and hemp-derived CBD-infused beverages,” said BevCanna president Melise Panetta in the press release. “We’ve been actively seeking U.S. and international growth opportunities for this portfolio, and Riviera is an ideal partner to advance this strategy. Their expertise and capacity to produce high-quality bottled beverages is an excellent fit for us.”

To view the full press release, visit https://cnw.fm/flzEJ

About BevCanna Enterprises Inc.

BevCanna Enterprises is a diversified health and wellness beverage and natural products company. BevCanna develops and manufactures a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, BevCanna owns a pristine alkaline spring water aquifer and a world-class, 40,000-square-foot, HACCP-certified manufacturing facility, with a bottling capacity of up to 210M bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with number-one U.S. cannabis beverage company Keef Brands. For more information about the company, please visit www.BevCanna.com.

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) RYAH Medtech Enters Exclusive Agreement with DelleD SAS

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has entered a definitively exclusive software development and product distribution agreement with its France-based partner, DelleD SAS, for the distribution of the RYAH Smart Inhaler. According to the update, the strategic agreement further defines the previously announced arrangement with DelleD to distribute RYAH Smart Inhalers in the territory of France and participate in the upcoming tender for the French government’s national experiment on patient use of medical cannabis. “In addition to distribution of the proprietary devices and accessories, the deal involves a statement of work (‘SOW’) for RYAH to develop customized software for DelleD that would cater to the French patients who intend to use and track their plant-based therapies via DelleD,” said Jordan Medley, head of Product Operations at RYAH, noting this project is the company’s second customized software development order. “Providing a robust data collection mechanism ensures more comprehensive patient feedback — and, consequently, accurate clinical trial results.”

To view the full press release, visit https://cnw.fm/SQyPi

About RYAH Group Inc.

RYAH is a big data and technology company focused on valuable predictive analysis in the global medical intake industry. The company manages a complete digital ecosystem leveraging both internet of things (“IoT”) and artificial intelligence (“AI”) to create a dynamic data service for the medical plant industry. It is developing a suite of IoT devices, including a dry-herb vaporizer device capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant dose management. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for pharmacies, clinics, growers, dispensaries, and licensed processors (“LPs”) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW — NIDA Boss Asks for Reconsideration of Marijuana Criminalization

Decades after the United States began a campaign to hamper drug use in the country, it is pretty clear that the war on drugs has been a failure. Intense policing coupled with harsh sentencing may have worked on other crimes, but in the case of cannabis, this approach only ensured that certain communities were punished harshly for cannabis-related crimes while others weren’t.

The nationwide campaign to decriminalize drug use may have gained a major supporter after the head of a top federal drug agency criticized America’s policy of treating drug use as a criminal problem rather than a public health issue.

The director of the National Institute on Drug Abuse (“NIDA”) Nora Volkov has in the past made it clear that she isn’t a big supporter of the country’s anti-drug laws. This time, she wrote an essay, titled “Addiction Should Be Treated, Not Penalized,” for the “Journal Health Affairs” where she argued that the time has come for the U.S. to stop handing out long sentences to individuals with low-level drug offenses. Although Volkov doesn’t explicitly endorse decriminalization, she made it clear that the current policies don’t work, especially for communities of color.

Most studies have found that Black and Latino communities are much more likely to be arrested for marijuana-related offenses compared to white communities despite similar usage rates. The drug policies that are currently in place have led to disproportionate enforcement against communities of color, Volkov says, and rather than hamper drug use, these policies can even increase the risk of overdose deaths. Punishment, especially the kind of punishment proffered in American courts, does not reduce the occurrence of substance use disorders, she writes. Rather, it increases an individual’s risk of experiencing a drug overdose once they are released from prison.

Despite the fact that we have decades’ worth of evidence proving that addiction is a medical problem not a criminal matter, the U.S. continues to criminalize drug addiction. In the interest of both “health equity and population well-being,” the U.S. must approach drug addiction as a public health issue,” Volkov notes. Not only will this allow people who are afflicted with substance use disorders to get the help they need, but it will ensure that communities of color aren’t the victim of disproportionate enforcement any anymore. Volkov writes that the country desperately needs to research public health-based alternatives such as drug courts, diversion programs and legislation decriminalizing drug possession.

In the meantime, she says, NIDA will double its focus on addressing substance use and addiction in minority communities.

If the voices of such high-ranking federal agency officials are heeded and cannabis policy reform is implemented at the federal level, the regulatory landscape within which industry actors such as Hero Technologies Inc. (OTC: HENC) operate will become much more clear.

NOTE TO INVESTORS: The latest news and updates relating to Hero Technologies Inc. (OTC: HENC) are available in the company’s newsroom at https://cnw.fm/HENC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Free Cannabis for COVID Jabs Turns Out to Be Popular

The latest data from the U.S. CDC indicates that approximately one-third of all adults in the country have received full vaccination against COVID-19. As the statistics of doses administered on a daily basis start dropping, health officials have turned their focus upon individuals who express hesitation to get the jab.

Smaller vaccination centers are mushrooming in a number of unexpected places, such as at strip clubs, to lure more people to get vaccinated. At the same time, people are being given different incentives to encourage them to get vaccinated. Incentives include savings bonds, cash and, in some cases, even booze.

One particular perk — free cannabis for those who have been vaccinated — has turned out to be a master stroke given the enthusiastic response it has generated among those in support of marijuana across the nation.

DCMJ, a pro-cannabis law reform group based in Washington, DC., started this trend by announcing in January this year that it was launching a campaign, dubbed “Joints for Jabs,” the provided free cannabis as a reward for every person who got vaccinated when the country rolled out its inoculation program.

The policy reform outfit says so far it has handed out in excess of 10,000 joints at several events organized outside vaccination locations in the nation’s capital. Those giveaways were an instant hit not just among people passing by but also among the staff vaccinating those who show up for the jab.

Adam Eidinger, co-founder of DCMJ, says he overheard a staff member who was vaccinating people telling individuals to step out and receive a free joint. This was after those inside the vaccination center had heard about the campaign outside.

It wasn’t long before DCMJ’s work in Washington caught on in New York, and NYMJ (a sister advocacy group to DCMJ) teamed up with DCMJ to stage similar campaigns when the 4/20 cannabis holiday came round.

On that day, Union Square in New York hosted a major event by NYMJ, and approximately 4,000 cannabis joints were handed out. On the same day, DCMJ also had events at 35 venues in Washington, DC, at which big giveaways were held.

Volunteers rolled all the cannabis that was given away in New York and they followed strict safety protocols to prevent the spread of infections, including COVID-19. The measures included wearing gloves and masks as well as avoiding licking the papers in which the cannabis was rolled. The campaigners say all the cannabis handed out was donated by people growing marijuana at home since existing laws made it hard for licensed marijuana companies to donate weed.

Some registered firms, such as Arizona-based the Mint dispensaries, have also found ways to hand out cannabis to vaccinated individuals who visit their stores. People qualifie for this perk by presenting their vaccination cards.

The proprietors of these companies hope the recipients see the perk as a reward and not an inducement to get vaccinated.

The foregoing shows that players in the cannabis sector are doing what they can to support the COVID-19 immunization drive, thereby adding to the other benefits such as employment opportunities that entities such as Sonoma Biologics Corp. bring to the jurisdictions where they operate.

NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Everything You Need to Know About Delta-8 THC

Long before lawmakers were considering legislation that would federally decriminalize cannabis, Congress passed the 2018 Farm Bill. Among other things, this legislation legalized the cultivation and sale of industrial hemp and its derivatives. Hemp is a form of cannabis that has less than 0.3% THC, meaning any products made from hemp or its derivatives do not cause users to get high. For the past year or so, one of the components found in hemp has been enjoying increased market visibility, especially in New York State.

If delta 8 THC sounds familiar, it’s probably because it reminds you of the component in cannabis that creates that feeling of intoxication. Hemp and cannabis produce hundreds of compounds called cannabinoids, including the famous CBD and delta-9 THC (tetrahydrocannabinol) responsible for cannabis’ effects. However, despite sharing a name and sporting a similar molecular structure, delta-8 THC is a completely different ball game. In New York, delta-8 THC products have been available for close to a year.

Many shops that specialize in CBD and other hemp-derived products also stock delta-8 THC products, usually in flower, vap, or edible form. How does this cannabinoid react with the body? According to Garry Colmey, a legal cannabis advocate who operates a indoor cannabidiol gardening outlet in Rome, Italy, delta-8 makes people “feel good.” The feeling lands somewhere between the those evoked by consuming CBD and THC, producing a mild sort of euphoria without the buzz cannabis is famous for.

Since hemp products must contain less than 0.3% THC to be considered legal, delta-8 THC leaves the userr with a sort of body euphoria rather than a head high, says Yardley Burgess. Burgess owns a number of Empire CBD retail shops in New York State, and he says delta-8 THC may also provide relief against pain and anxiety as well as boost feelings of relaxation. The popularity of the milder cannabinoid isn’t just limited to New York; delta-8 THC is going nationwide.

In March this year, a “Forbes” article reported that that delta-8 THC was quickly becoming the most exciting and intoxicating product in the hemp industry. Still, delta-8 THC has plenty of detractors, and the article noted that the booming sector may soon fall. Several states, including Colorado, Alaska, Arkansas, Montana, Delaware, Idaho, Arizona and Mississippi, have banned delta-8 THC, as other states are looking into such hemp derivatives. Kim Stuck, a former cannabis regulator who now runs Allay, a consulting service that advises and provides assistance to businesses in the cannabis space, says this could be because the industry is still brand new and most states are still uncertain about minor cannabinoids such as delta-8 tetrahydrocannabinol.

Businesses in this space may be reaping profits, but things may soon change as laws and regulations catch up. Recently, the Drug Enforcement Administration (“DEA”) proposed classifying delta-8 THC as a controlled substance, but the rule change hasn’t been made yet.

Hopefully, the rule changes imposed in various jurisdictions take note of the therapeutic potential of various cannabinoids as the therapeutic formulations undergoing trials by XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) and other companies indicate.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://cnw.fm/XPHYF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Public Defenders Accuse Bronx DA of Dragging Feet on Dropping Pending Cannabis Cases

In April, New York passed one of the most progressive recreational cannabis laws in the country, joining a small but growing number of states that now allow adult-use cannabis. On top of allowing adults aged 21 and over to grow, purchase and possess cannabis, the bill also provided provisions for dismissing prior cannabis-related charges and expunging such offenses from people’s records. However, more than one month after New York state legalized recreational cannabis, a number of New York residents still have pending cases and even arrest warrants for offenses that are now considered legal under state law.

Each of the five administrative units, or boroughs, in New York City has got its own district attorney’s office, and public defenders in the Bronx have accused the Bronx DA of dragging his feet rather than making haste to dismiss pending cannabis-related cases. On April 20, 2021, the public defenders sent Bronx DA Darcel Clark’s office a letter urging him to conduct the affairs of his office in line with the Marijuana Regulation and Taxation Act (“MRTA”). The defenders estimate that there are currently hundreds of pending cases involving serious charges such as criminal possession or sale of cannabis that are currently legal or considered lesser violations.

Despite the passage of the recreational cannabis law, those cases are still hovering over people’s heads, says Eli Northrup, a lawyer from Bronx Defenders. For instance, 41 people from the Bronx have been arraigned before court on marijuana charges, and their court dates are coming up. There are also cases involving individuals who, after being arrested, were given desk appearance tickets to present themselves in court as well as warrants issued for people who failed to show up before court or did not pay their fine.

Northrup says this group probably includes individuals with warrants that are decades old, making it the largest category of individuals impacted by the Bronx DA’s inaction. Ruben Fernandez, another attorney allied with the Bronx Defenders, says plenty of judges have been throwing out cannabis-related charges as accused persons appear in their courts. Ideally, individuals who were charged with offenses that are now considered legal would have their records automatically expunged of the offense.

However, some issues such as clearing warrants may take some time, exposing people with such warrants to the risk of arrest if an officer stops them before the process is complete. In fact, some people may not even be aware that there are warrants out for their arrest, Fernandez says. Court dates are an extra hustle, causing people to lose work hours and forcing them to find child care, which can be quite costly.

According to a spokesperson from the Bronx DA’s office, the DA is currently evaluating cases to determine if they fit the criteria for dismissal.

It is unfortunate that some prosecutors seem to be in no hurry to drop charges that can no longer be sustained under the current marijuana laws in New York state; moreover, this is coming at a time when several companies in different jurisdictions, such as RYAH Group Inc. (CSE: RYAH), have a range of products including the RYAH Smart Pen, which help patients take precise doses of their medical cannabis. This illustrates how unnecessary it is to criminalize a substance with therapeutic potential.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.